Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Equity Average (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Equity Average for 8 consecutive years, with $146.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 141.85% to $146.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146.7 million through Dec 2025, up 141.85% year-over-year, with the annual reading at $94.4 million for FY2025, 19.73% up from the prior year.
  • Equity Average for Q4 2025 was $146.7 million at Whitehawk Therapeutics, down from $164.6 million in the prior quarter.
  • The five-year high for Equity Average was $196.9 million in Q2 2025, with the low at -$19.2 million in Q1 2021.
  • Average Equity Average over 5 years is $110.6 million, with a median of $127.7 million recorded in 2022.
  • The sharpest move saw Equity Average crashed 78.59% in 2021, then surged 780.43% in 2022.
  • Over 5 years, Equity Average stood at $143.7 million in 2021, then grew by 13.98% to $163.7 million in 2022, then crashed by 31.79% to $111.7 million in 2023, then tumbled by 45.68% to $60.7 million in 2024, then surged by 141.85% to $146.7 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $146.7 million, $164.6 million, and $196.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.